开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R692

References41

[1]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. doi:10.1016/S0140-6736(12)60033-6 URL
[2]	Kidney Disease: Improving Global Outcomes KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl, 2012, 2(4):279-335. doi:10.1038/ki.1972.107 URL
[3]	World Health Organization. Iron deficiency anemia:assessment, prevention and control[G/OL]. 2001. https://www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdfhttps://www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdf.
[4]	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018修订版)[J]. 中华肾脏病杂志, 2018, 34(11):860-866. doi:10.3760/cma.j.issn.1001-7097.2018.11.012
[5]	Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study[J]. Medicine (Baltimore), 2016, 95(24): e3872. doi:10.1097/MD.0000000000003872 URL
[6]	束金莲, 李贺, 姚少峰, 等. 初始血液透析患者贫血的相关危险因素回顾性研究[J/OL]. 中国现代医学杂志, 2020. https://kns.cnki.net/kcms/detail/43.1225.R.20200707.1308.024.html
[7]	Zhou QG, Jiang JP, Wu SJ, et al. Current pattern of Chinese dialysis units: a cohort study in a representative sample of units[J]. Chin Med J (Engl), 2012, 125(19): 3434-3439.
[8]	Zuo L, Wang M, Hou F, et al. Anemia management in the China dialysis outcomes and practice patterns study[J]. Blood Purif, 2016, 42(1): 33-43. doi:10.1159/000442741 URL
[9]	Ni Z, Jin H, Jiang G, et al. A telemedicine-based registration system for the management of renal anemia in patients on maintenance hemodialysis: multicenter study[J]. J Med Internet Res, 2019, 21(5): e13168. doi:10.2196/13168 URL
[10]	Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia[J]. BMC Nephrol, 2016, 17(1): 97. doi:10.1186/s12882-016-0312-9pmid:27460779
[11]	Hazin MAA. Anemia in chronic kidney disease[J]. Rev Assoc Med Bras (1992), 2020, 66 Suppl 1: s55-s58.
[12]	王莉君, 袁伟杰. 关于肾性贫血治疗相关指南与共识回顾[J]. 中国血液净化, 2018, 17(1): 1-5.
[13]	Covic A, Jackson J, Hadfield A, et al. Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease[J]. Adv Ther, 2017, 34(7): 1662-1672. doi:10.1007/s12325-017-0566-z URL
[14]	Ganz T, Aronoff GR, Gaillard CAJM, et al. Iron administration, infection, and anemia management in CKD: untangling the effects of intravenous iron therapy on immunity and infection risk[J]. Kidney Med, 2020, 2(3): 341-353. doi:10.1016/j.xkme.2020.01.006 URL
[15]	Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(2): e0117383. doi:10.1371/journal.pone.0117383 URL
[16]	Gafter-gvili A, Schechter A, Rozen-zvi B. Iron deficiency anemia in chronic kidney disease[J]. Acta Haematol, 2019, 142(1): 44-50. doi:10.1159/000496492 URL
[17]	Shepshelovich D, Rozen-Zvi B, AVNI T, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis[J]. Am J Kidney Dis, 2016, 68(5): 677-690. doi:S0272-6386(16)30125-1pmid:27321965
[18]	Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis[J]. N Engl J Med, 2019, 380(5): 447-458. doi:10.1056/NEJMoa1810742 URL
[19]	Wyatt CM, Drueke TB. High-dose Ⅳ iron for anemia correction in chronic kidney disease[J]. Kidney Int, 2019, 95(4): 727-730. doi:10.1016/j.kint.2019.01.013 URL
[20]	Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis[J]. J Am Soc Nephrol, 2015, 26(2): 493-503. doi:10.1681/ASN.2014020212 URL
[21]	Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review[J]. Curr Opin Nephrol Hypertens, 2017, 26(3): 214-218. doi:10.1097/MNH.0000000000000317 URL
[22]	Womack R, Berru F, Panwar B, et al. Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a ran-domized trial[J]. Clin J Am Soc Nephrol, 2020, 5(9):1251-1258.
[23]	Sakaguhi Y, Hamano T, Wada A, et al. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis[J]. J Am Soc Nephrol, 2019, 30(6): 1037-1048. doi:10.1681/ASN.2018101007 URL
[24]	Thavarajah S, Choi MJ. The use of erythropoiesis-stimulating agents in patients with CKD and cancer: a clinical approach[J]. Am J Kidney Dis, 2019, 74(5): 667-674. doi:S0272-6386(19)30767-Xpmid:31395400
[25]	René É, Lazrak HH, Laurin LP, et al. Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a ne-sted case-control study[J]. Nephrol Dial Transplant, 2017, 32(6): 1047-1052.
[26]	马红珍. 慢性肾脏病肾性贫血的治疗策略[J]. 浙江医学, 2020, 42(11): 1103-1105.
[27]	陈楠. 罗沙司他在慢性肾脏病患者肾性贫血治疗中的应用[J]. 中华内科杂志, 2019, 58(12): 919-920.
[28]	Chen N, Hao C, Liu BC, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Eng J Med, 2019, 381(11):1011-1022. doi:10.1056/NEJMoa1901713 URL
[29]	Chen N, Hao C, Liu BC, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi:10.1056/NEJMoa1813599 URL
[30]	Akizawa T, Yamaguchi Y, Otsuka T, et al. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients not on dialysis[J]. Nephron, 2020, 144(8): 372-382. doi:10.1159/000508100 URL
[31]	Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan[J]. J Am Soc Nephrol, 2020(7): 1628-1639. doi:10.1681/ASN.2019060623pmid:32493693
[32]	Zheng Q, Yang H, Fu X, et al. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis[J]. Nephrol Dial Transplant, 2020. [Epub ahead of print].
[33]	Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a ran-domized, double-blind, phase 3 trial[J]. Clin J Am Soc Nephrol, 2020, 15(8): 1155-1165. doi:10.2215/CJN.16011219 URL
[34]	Nangaku M, Kondo K, Takabe S, et al. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: a phase 3 open-label study in Japan[J]. Ther Apher Dial, 2020. [Epub ahead of print].
[35]	Akizawa T, Taguchi M, Matsuda Y, et al. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase Ⅲ studies[J]. BMJ Open, 2019, 9(6): e026602. doi:10.1136/bmjopen-2018-026602 URL
[36]	Yamamoto H, Taguchi M, Matsuda Y, et al. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies[J]. BMJ Open, 2019, 9(6): e026704. doi:10.1136/bmjopen-2018-026704 URL
[37]	Agarwal AK, Yee J. Hepcidin[J]. Adv Chronic Kidney Dis, 2019, 26(4): 298-305. doi:10.1053/j.ackd.2019.04.005 URL
[38]	Roth MP, Meynard D, Coppin H. Regulators of hepcidin expression[J]. Vitam Horm, 2019, 110: 101-129.
[39]	Renders L, Budde K, Rosenberger C, et al. First-in-human Phase Ⅰ studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis[J]. PLoS One, 2019, 14(3): e0212023. doi:10.1371/journal.pone.0212023 URL
[40]	Voors-pette C, Lebozec K, Dogterom P, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-ferroportin antibody in patients with anemia due to chronic renal failure[J]. Blood, 2016, 128 (Suppl 4): 1280. doi:10.1182/blood.V128.22.1280.1280 URL
[41]	Katsarou A, Pantopoulos K. Hepcidin therapeutics[J]. Pharmaceuticals(Basel), 2018, 11(4): 127.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References41

Related Articles9

Recommended Articles

Metrics

Comments

[1]	ZHANG Xiaoyan, XU Jing, QU Bin.Effect of serum vitamin D level on renal function in elderly patients with chronic kidney disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 307-312.
[2]	ZHANG Chunli, XU Jing, PAN Xiaoxia, HU Xiaofan, LI Ya.Analysis of clinical and histological features of IgG4-related kidney disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 214-219.
[3]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(05): 366-370.
[4]	XUAN Yingli, CHEN Feihong, QIN Li, HE Ruibin, PANG Shiqing, YUAN Jiangzi.Correlation analysis of vitamin D and nocturnal blood pressure in the patients with chronic kidney disease[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 246-250.
[5]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 49-52.
[6]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 4-9.
[7]	WANG Xuejie, CHEN Zijin, DU Wen, GU Feifei, YU Haijin, ZHANG Wen, CHEN Xiaonong.Risk factors of acute kidney injury in the patients with bloodstream infection caused by different pathogens[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 22-26.
[8]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 15-17.
[9]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 1-3.